Product Information
IMATINIB MESYLATE 100 MG TAB is a generic product labeled by BluePoint Laboratories, priced at $0.8525 per EA under NDC 68001049005. Its NADAC has been published 192 times since Jun 22, 2022.
FDA first approved this application on Dec 3, 2015.
Strength
100 mg/1
Manufacturer
BluePoint LaboratoriesNDC
68001049005
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
2/18/2026
Active Ingredients
IMATINIB MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA078340FDA Approved
12/3/2015
On Market Since
3/26/2021
Pharmacological Classes
Price Statistics
The NADAC for IMATINIB MESYLATE 100 MG TAB has been published 192 times since Jun 22, 2022, and over the history we have for it it has risen 5.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8525 per EA |
|---|---|
| All-time high | $0.9761 (Sep 10, 2025) |
| All-time low | $0.3890 (May 22, 2024) |
| 52-week high | $0.9248 |
| 52-week low | $0.8525 |
| Median price | $0.6256 |
| Average price | $0.6997 |
| Largest weekly change | -35.6% (May 22, 2024) |
| Weeks tracked | 192 |
| Tracking since | Jun 22, 2022 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
-7.8%
3Y
+40.0%
5Y
N/A
All
+5.0%
Last surveyed Feb 18, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 42% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
BluePoint Laboratories manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
imatinib mesylate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IMATINIB MESYLATE 100 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for IMATINIB MESYLATE 100 MG TAB, manufactured by BluePoint Laboratories, is $0.8525 per EA (NDC 68001049005), effective Feb 18, 2026.
How has the price of IMATINIB MESYLATE 100 MG TAB changed over time?
Over the history we have for it, the NADAC for IMATINIB MESYLATE 100 MG TAB has risen 5.0%. It has been tracked across 192 weekly CMS publications since Jun 22, 2022.
What are the highest and lowest recorded NADAC prices for IMATINIB MESYLATE 100 MG TAB?
Since Jun 22, 2022, the NADAC for IMATINIB MESYLATE 100 MG TAB has ranged from a low of $0.3890 (May 22, 2024) to a high of $0.9761 (Sep 10, 2025), with a median of $0.6256 per EA.
Are there cheaper alternatives to IMATINIB MESYLATE 100 MG TAB?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IMATINIB MESYLATE 100 MG TAB, is $0.4912 per EA — about 42% below IMATINIB MESYLATE 100 MG TAB.
Who manufactures IMATINIB MESYLATE 100 MG TAB?
IMATINIB MESYLATE 100 MG TAB (NDC 68001049005) is labeled by BluePoint Laboratories, and CMS classifies it as a generic product.